文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

更新版HACOR评分用于预测无创通气失败:一项多中心前瞻性观察研究

An updated HACOR score for predicting the failure of noninvasive ventilation: a multicenter prospective observational study.
PubMed 文献 · Crit Care · 2022-07-03
一句话结论在低氧性呼吸衰竭患者中,NIV后1–2小时更新版HACOR评分预测失败AUC达0.85(训练队列)与0.78(验证队列),评分>14分时失败率83.7%。

本研究在中国和土耳其18家医院开展多中心前瞻性观察,纳入因低氧性呼吸衰竭接受NIV的患者,重庆1451例为训练队列,重庆以外728例为外部验证队列。将肺炎、心源性肺水肿、肺型ARDS、免疫抑制、脓毒性休克及SOFA评分6项基线变量加入原HACOR评分形成更新版HACOR。NIV后1–2小时更新版HACOR预测NIV失败的AUC在训练队列为0.85(95%CI 0.84–0.87),验证队列为0.78(0.75–0.81);在1–2、12、24小时各时点均高于原HACOR(P均<0.01)。更新版HACOR评分7、10.5、14分对应NIV失败概率分别为25%、50%、75%。作者认为该评分可用于NIV决策辅助。

要点

  • NIV后1–2小时更新版HACOR评分预测失败的AUC:训练队列0.85(95%CI 0.84–0.87),验证队列0.78(0.75–0.81)。
  • 更新版HACOR评分7、10.5、14分对应NIV失败概率分别为25%、50%、75%。
  • NIV后1–2小时评分≤7、7.5–10.5、11–14、>14分者NIV失败率分别为12.4%、38.2%、67.1%、83.7%。
  • 更新版HACOR在1–2、12、24小时预测AUC均高于原HACOR(训练队列0.85 vs 0.80、0.86 vs 0.81、0.85 vs 0.82;验证队列0.78 vs 0.71、0.79 vs 0.74、0.81 vs 0.76;P均<0.01)。
  • 基线肺炎、心源性肺水肿、肺型ARDS、免疫抑制、脓毒性休克及SOFA评分与NIV失败强相关,已纳入更新版评分。

适用人群与场景

  • 因低氧性呼吸衰竭接受NIV的患者;训练队列为中国重庆1451例,外部验证队列为重庆以外728例(中国和土耳其共18家医院)。

诊断标准与关键阈值

  • 更新版HACOR评分由原HACOR评分加6项基线变量(肺炎、心源性肺水肿、肺型ARDS、免疫抑制、脓毒性休克、SOFA评分)构成。
  • NIV后1–2小时更新版HACOR评分7分对应NIV失败概率25%,10.5分对应50%,14分对应75%。

研究设计与关键结果

  • 多中心前瞻性观察研究,18家医院,训练队列1451例,外部验证队列728例;纳入因低氧性呼吸衰竭接受NIV的患者。
  • NIV后1–2小时更新版HACOR预测NIV失败的AUC:训练队列0.85(95%CI 0.84–0.87),验证队列0.78(0.75–0.81)。
  • 训练队列更新版HACOR vs 原HACOR的AUC:1–2小时0.85 vs 0.80,12小时0.86 vs 0.81,24小时0.85 vs 0.82,P均<0.01。
  • 验证队列更新版HACOR vs 原HACOR的AUC:1–2小时0.78 vs 0.71,12小时0.79 vs 0.74,24小时0.81 vs 0.76,P均<0.01。
  • NIV后1–2小时更新版HACOR评分≤7、7.5–10.5、11–14、>14分者NIV失败率分别为12.4%、38.2%、67.1%、83.7%。

证据类型、等级与局限

  • 证据类型:多中心前瞻性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为更新版HACOR评分对低氧性呼吸衰竭患者的NIV失败有较高预测力,可用于NIV使用时的决策辅助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Heart rate, acidosis, consciousness, oxygenation, and respiratory rate (HACOR) have been used to predict noninvasive ventilation (NIV) failure. However, the HACOR score fails to consider baseline data. Here, we aimed to update the HACOR score to take into account baseline data and test its predictive power for NIV failure primarily after 1-2 h of NIV.

METHODS: A multicenter prospective observational study was performed in 18 hospitals in China and Turkey. Patients who received NIV because of hypoxemic respiratory failure were enrolled. In Chongqing, China, 1451 patients were enrolled in the training cohort. Outside of Chongqing, another 728 patients were enrolled in the external validation cohort.

RESULTS: Before NIV, the presence of pneumonia, cardiogenic pulmonary edema, pulmonary ARDS, immunosuppression, or septic shock and the SOFA score were strongly associated with NIV failure. These six variables as baseline data were added to the original HACOR score. The AUCs for predicting NIV failure were 0.85 (95% CI 0.84-0.87) and 0.78 (0.75-0.81) tested with the updated HACOR score assessed after 1-2 h of NIV in the training and validation cohorts, respectively. A higher AUC was observed when it was tested with the updated HACOR score compared to the original HACOR score in the training cohort (0.85 vs. 0.80, 0.86 vs. 0.81, and 0.85 vs. 0.82 after 1-2, 12, and 24 h of NIV, respectively; all p values < 0.01). Similar results were found in the validation cohort (0.78 vs. 0.71, 0.79 vs. 0.74, and 0.81 vs. 0.76, respectively; all p values < 0.01). When 7, 10.5, and 14 points of the updated HACOR score were used as cutoff values, the probability of NIV failure was 25%, 50%, and 75%, respectively. Among patients with updated HACOR scores of ≤ 7, 7.5-10.5, 11-14, and > 14 after 1-2 h of NIV, the rate of NIV failure was 12.4%, 38.2%, 67.1%, and 83.7%, respectively.

CONCLUSIONS: The updated HACOR score has high predictive power for NIV failure in patients with hypoxemic respiratory failure. It can be used to help in decision-making when NIV is used.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Duan J, Chen L, Liu X, et al. An updated HACOR score for predicting the failure of noninvasive ventilation: a multicenter prospective observational study. Crit Care. 2022. PMID: 35786223. doi:10.1186/s13054-022-04060-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。